{"entity":{"id":"nct05986851","kind":"trial","name":"Azeliragon in MGMT Unmethylated Glioblastoma","aka":[],"tldr":"A phase 2 trial of Azeliragon in glioma & glioblastoma, run by Cantex Pharmaceuticals, active and no longer recruiting.","summary":"Azeliragon in MGMT Unmethylated Glioblastoma is a phase 2 interventional study registered as NCT05986851 by Cantex Pharmaceuticals, with 30 participants enrolled, started 2023-09-12 and due to reach its primary completion in 2026-09-30. Interventions recorded: Azeliragon.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05986851","url":"https://clinicaltrials.gov/study/NCT05986851"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["medpace"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05986851","phase":"2","setting":"A Phase II Study to Assess Safety and Preliminary Evidence of a Therapeutic Effect of Azeliragon in Patients With MGMT Unmethylated Glioblastoma","sponsor":"Cantex Pharmaceuticals","enrolled":30,"outcomes":[]},"route":"/trials/nct05986851/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"company":[{"id":"medpace","kind":"company","name":"Medpace","route":"/companies/medpace/"}]}}